Epigenetic regulation of cancer stem cell plasticity and relapse competence in EGFR-mutant lung cancer

Submitted by Anonymous on

Abstract Cancer stem cell (CSC) plasticity is increasingly linked to therapy resistance, yet CSC identity is still often inferred from persistence, stemness markers, or short-term regenerative assays. EGFR-mutant non–small-cell lung cancer is a useful setting in which to examine this...

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

Submitted by Anonymous on

NEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073)...

ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer ArriVent BioPharma, Inc. Mon, October 19, 2026 at 2:01 PM GMT+2...

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Submitted by Anonymous on

Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor...

Quanta Therapeutics Announces Presentation of QTX3034 Clinical Combination Data with Anti-EGFR and Chemotherapy in Colorectal Cancer (CRC) at ESMO and Fast Track Designation for Patients with KRAS...

Submitted by Anonymous on

RADNOR, Pa. and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Quanta Therapeutics, a privately held, clinical-stage biopharmaceutical company leading the development of innovative therapeutics for RAS-driven cancers, today announced that it will present clinical data for its...

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Submitted by Anonymous on

PRINCETON, N.J. & CAMBRIDGE, Mass., October 19, 2026--Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell...

Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS Metastases

Submitted by Anonymous on

PRINCETON, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 19, 2026-- Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small...

Cardamonin attenuates SH-SY5Y neuronal apoptosis induced by LPS-activated microglia via modulation of the EGFR/PI3K/AKT1/ERK/NF-κB pathway

Submitted by Anonymous on

IntroductionMicroglial activation-induced neuroinflammation plays a critical role in the pathogenesis of neurodegenerative diseases. Cardamonin (CD, 2′,4′-di Abstract Introduction: Microglial activation-induced neuroinflammation plays a critical role in the pathogenesis of neurodegenerative diseases. Cardamonin (CD, 2′,4′-dihydroxy-6′-methoxychalcone), a natural chalcone flavonoid present in...

Subscribe to Newsfeed